ERBB2 and breast cancer: FA synthase (FASN) overexpression induces resistance to anti-tumoral drugs such as doxorubicin and mitoxantrone in breast cancer cells [64], docetaxel resistance in HER2-positive breast cancer [65], gemcitabine resistance in pancreatic cancer [66], and cisplatin resistance in ovarian cancer [67].